Implications of COVID-19 infection on patients with uveitis under biologic treatment

5Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background/aims To investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic. Methods In this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020. Results A total of 59 patients were identified. Behçet's disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension. Conclusion Uveitis patients under biologic therapy can be silent carriers for COVID-19.

Author supplied keywords

Cite

CITATION STYLE

APA

Albloushi, A. F., Alfawaz, A. M., & Abu El Asrar, A. M. (2021). Implications of COVID-19 infection on patients with uveitis under biologic treatment. British Journal of Ophthalmology, 106(11), 1538–1541. https://doi.org/10.1136/bjophthalmol-2020-318577

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free